The European Commission has approved Chiesi’s Trimbow Nexthaler extrafine beclometasone dipropionate / formoterol fumarate / glycopyrronium DPI for the treatment of moderate to severe COPD in patients not adequately treated with an ICS/LABA or LABA/LAMA combination, the company said.
Chiesi’s Trimbow triple combination MDI was approved in Europe for the treatment of COPD in August 2017, and the Trimbow MDI was approved in Europe for the treatment of asthma in February 2021. Chiesi asserts that “It is extremely important to have both options available for different patients’ needs as pMDIs and DPIs are the most commonly used devices for patients with chronic respiratory diseases such as COPD.”
Chiesi Group Chief Commercial Officer Alessandro Chiesi commented, “With the marketing authorization for our triple therapy in a NEXThaler device in the EU, the Chiesi Group reinforces its commitment to providing a broad portfolio of formulations and devices to COPD patients and physicians. Chiesi triple therapy is today the first and only triple fixed combination treatment providing both pMDI and DPI devices as options for patients and physicians. We aim to make this treatment available to appropriate patients in Europe as soon as possible.”
Read the Chiesi press release.
